Cover Image
市場調查報告書

全球心臟生物標記市場

Cardiac Biomarkers

出版商 Global Industry Analysts, Inc. 商品編碼 225214
出版日期 內容資訊 英文 236 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球心臟生物標記市場 Cardiac Biomarkers
出版日期: 2016年04月01日 內容資訊: 英文 236 Pages
簡介

本報告提供全球心臟生物標記市場相關調查,彙整各地區趨勢與2015∼2022年的市場成長預測,及加入此市場的主要企業簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 概要
    • 心臟標記及其特性
    • 現在及未來方案
    • 即使北美佔有最大佔有率亞太地區市場氣勢仍然與日俱增
    • 各類型市場分析
    • 競爭環境
  • 市場成長的促進要素,趨勢,課題
  • 產品概要
    • 心臟標記化驗檢驗的必要性
    • 心臟標記和心肌梗塞
    • 心肌梗塞後的連鎖反應
    • 心肌梗塞後的行動計劃
    • AMI標記檢驗的通訊協定
    • 心臟標記和鬱血性心衰竭
    • 心臟標記的種類 其他
  • 產品引進
  • 近幾年的產業活動
  • 主要企業
    • Abbott Diagnostics, Inc.
    • Alere, Inc.
    • Beckman Coulter, Inc.
    • BG Medicine, Inc.
    • biomerieux SA
    • Boditech Med Inc.
    • Labsystems Diagnostics OY
    • LifeSign LLC
    • LSI Medience Corporation
    • Ortho-Clinical Diagnostics, Inc.
    • Randox Laboratories Ltd
    • Response Biomedical Corp.
    • Roche Diagnostics Corp.
    • Siemens Healthcare Diagnostics, Inc.
    • Singulex, Inc.
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

競爭環境

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-1632

This report analyzes the worldwide markets for Cardiac Biomarkers in US$ Thousand by the following Testing Locations: Laboratory Testing, and Point of Care Testing. The Global, US and European markets are further analyzed by the following Test Types: Cardiac Troponin, BNP and NT-proBNP, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 44 companies including many key and niche players such as -

Abbott Diagnostics, Inc.
Alere, Inc.
Beckman Coulter, Inc.
BG Medicine, Inc.
biomerieux SA

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definition and Scope of Study
    • Cardiac Biomarkers
      • Testing Location
        • Laboratory Testing
        • Point of Care Testing
      • Types of Cardiac Biomarkers
        • Cardiac Troponin
        • Natriuretic Peptides
        • BNP (B-type Natriuretic Peptide)
        • NT-proBNP (N-terminal proBNP)
        • Others
        • Creatine Kinase-MB (CK-MB)
        • Myoglobin

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Curtain Raiser
  • Major Cardiac Markers and their Properties
  • Current and Future Scenario
  • North America Corners Biggest Slice, Asia-Pacific to Dictate Market Momentum
  • Laboratory Testing Remains Gold Standard, POC Testing Rapidly Gains Traction
  • Analysis by Type of Cardiac Biomarker Assay/Test
    • Emerging Markets, New Product Introductions Hold Key to Reviving Saturated Cardiac Troponin Assays Market
  • Competitive Landscape
  • Intense Competition among Players in the Cardiac Diagnostics Market
  • Leading Vendors Focus on Curtailing Turnaround Time of POC Cardiac Testing Kits
    • Cardiac Markers Point-Of-Care Testing (POC) Cardiac Testing Segment: Major Players and their Operating Brands

2. MARKET GROWTH DRIVERS, TRENDS & ISSUES

  • The Grim Reality of Mounting Economic and Social Burden of Cardiovascular Disease
    • Table 1: Prevalence of Heart Failure in Select Countries (includes corresponding Graph/Chart)
  • Population Explosion, Ballooning Geriatric Populace, Longer Life Expectancy Contributing to Rising Tide of CVDs
    • Table 2: Global Population Estimates (in Billion): 2000-2050P (includes corresponding Graph/Chart)
    • Table 3: Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2000, 2011, and 2020 (includes corresponding Graph/Chart)
    • Table 4: Global Aging Population (in Thousands) by Age Group: 1975, 2000, 2025, and 2050 (includes corresponding Graph/Chart)
    • Table 5: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013 (includes corresponding Graph/Chart)
    • Table 6: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
    • Table 7: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
  • Cardiac Biomarkers Hold the Key to Timely, Accurate Diagnosis & Prognosis
  • Commercialization of Novel Biomarkers to Drive Market Growth
  • Personalized Medicine, Companion Diagnostics Open Up Opportunities for Cardiac Biomarker Developers
  • Cardiac Biomarkers - a Powerful Tool for Patient Triaging
  • Cardiac Biomarkers Market Transitions from Mono-Marker to Multi-Marker Assays
  • Government Support Instrumental for Boosting Market Momentum
  • Secretoneurin Biomarker - a Potential Game Changer for Diagnosis of Cardiac Arrhythmias
  • High-Performance Techniques Drive Biomarker Discovery in Cardiology
  • Biomarkers for Acute Coronary Syndromes (ACS): A Leading Segment
  • Biomarkers - A Promising Diagnostic Tool for ACS
  • Biomarker Discovery for ACS to Undergo Significant Changes
  • Cardiac Biomarker Play Critical Role in Stroke Diagnosis
  • Cardiac Biomarkers to Find a Place in Neonatal Diagnosis and Treatment
  • Specificity, Sensitivity, Side Effects, Cost Concerns Hinder Market Growth

3. PRODUCT OVERVIEW

  • Necessity of a Cardiac Marker Assay Test
  • Cardiac Markers and Myocardial Infarction (MI)
  • Chain Reaction after an Event of MI
  • Action Plan after an Event of MI
  • Protocol for Conducting AMI Markers Tests
    • Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations
  • Cardiac Markers and Congestive Heart Failure (Chf)
  • Key Facts
  • Types of Cardiac Biomarkers
  • Major Cardiac Markers and their Properties
  • Creatine Kinase - The Gold Standard Losing Sheen
    • Isomers
    • Kinetics
    • Purpose of Test and When to Order
    • Evaluation
    • Points to remember
  • Cardiac Troponin
    • Troponin Tissue-Specific Subtypes
    • Other Diseases
    • Uses of Troponin Tests
    • New Advanced High-sensitivity (Hs) Cardiac Troponin Tests
  • Myoglobin
    • Purpose of Test and When to Order
    • Testing and Evaluation
    • Points of Caution
  • Natriuretic Peptides
    • BNP (B-type Natriuretic Peptide)
    • NT-proBNP (N-terminal proBNP)
      • Purpose of Tests and When to Order
      • Testing and Evaluation
      • Points to Remember
      • Introduction of BNP Test and the Changing Market Scenario in the Segment: A Review
      • Choosing the Right BNP and NT proBNP Assay Kit in the Market
      • Evolution of BNP and NT proBNP Market
      • NT-proBNP is superior to BNP in Predicting Mortality in Heart Failure Patients, with Reduced Kidney Function
  • Other Important Cardiac Biomarkers
    • Homocysteine
    • C-Reactive Protein
    • Plasminogen Activator Inhibitor-1
    • D-Dimer
      • Thrombus Precursor Protein
    • Galectin-3 Biomarker
    • Galectin-3: An Overview of Clinical Studies
      • Galectin-3: Overview of Clinical Studies in Cardiovascular Disease Diagnosis
    • Potential Future Cardiac Biomarkers
  • Location of Cardiac Biomarker Testing
  • Laboratory Cardiac Testing
  • Point-of-Care Cardiac Testing

4. PRODUCT INTRODUCTIONS

  • Singulex Secures US Patent for Cardiac Troponin I and T Biomarkers for Detecting CVDs
  • Singulex Wins European Patent for Cardiac Troponin I and T Biomarkers for Detecting Cardiac Damage
  • Critical Diagnostics Receives China FDA Clearance for Clinical Use of Presage ST2 Assay
  • Critical Diagnostics Secures CE Mark for Aspect-PLUS ST2 Test
  • Roche Diagnostics Introduces Improved Cardiac POC Troponin T test for cobas h 232 System
  • BG Medicine Receives US Patent for Galectin-3 and Cardiac Resynchronization Therapy
  • Critical Diagnostics Unveils Aspect-LF ST2 Test
  • Olink Bioscience Unveils Proseek Multiplex CVD I96x96 Protein Biomarker Panel
  • BG Medicine Gains AHA and ACCF Recognition for Galectin-3 Testing

5. RECENT INDUSTRY ACTIVITY

  • Eurofins Scientific Completes Takeover of Boston Heart Diagnostics Corp.
  • Lee Biosolutions Steps Up Investment for Development of High Value Cardiac Markers
  • MaRS Innovation Enters into Collaboration with Johnson & Johnson Innovation and Janssen
  • ACS Biomarker BV Establishes Mirnext BV
  • Critical Diagnostics Releases Results of Study on Cardiac Biomarker ST2

6. FOCUS ON SELECT PLAYERS

  • Abbott Diagnostics, Inc. (USA)
  • Alere, Inc. (USA)
  • Beckman Coulter, Inc. (USA)
  • BG Medicine, Inc. (USA)
  • biomerieux SA (France)
  • Boditech Med Inc. (South Korea)
  • Labsystems Diagnostics OY (Finland)
  • LifeSign LLC (USA)
  • LSI Medience Corporation (Japan)
  • Ortho-Clinical Diagnostics, Inc. (USA)
  • Randox Laboratories Ltd. (UK)
  • Response Biomedical Corp. (Canada)
  • Roche Diagnostics Corp. (Switzerland)
  • Siemens Healthcare Diagnostics, Inc. (USA)
  • Singulex, Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

  • Cardiac Biomarkers Testing By Geographic Region
    • Table 8: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 9: World Historic Review Analysis for Cardiac Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 10: World 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
  • Cardiac Biomarkers Testing By Location of Testing
    • Table 11: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 12: World Historic Review Analysis for Cardiac Biomarkers in Laboratory Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 13: World 14-Year Perspective for Cardiac Biomarkers in Laboratory Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
    • Table 14: World Recent Past, Current and Future Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 15: World Historic Review Analysis for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 16: World 14-Year Perspective for Cardiac Biomarkers in Point-of-Care (POC) Testing by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
  • Cardiac Biomarkers Market by Assay Test Type
    • Table 17: World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 18: World Historic Review Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 19: World 14-Year Perspective for Cardiac Biomarkers by Test Type - Percentage Breakdown of Dollar Revenues for Cardiac Troponin, BNP & NT-proBNP, and Others Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current and Future Analysis
    • Statistics for Cardiovascular Diseases and Stroke, and Related Risk Factors and Costs in the US
    • Table 20: Prevalence of Cardiovascular Disease in US Adult Population by Gender and Age (2009-2012): Prevalence Percentage of CVDs for Males and Females of Age Groups - 20-39 Years, 40-59 Years, 60-79 Years, and 80 Years & Above (includes corresponding Graph/Chart)
    • Table 21: Prevalence of Stroke in US Adult Population by Gender and Age (2009-2012): Prevalence Percentage of CVDs for Males and Females of Age Groups - 20-39 Years, 40-59 Years, 60-79 Years, and 80 Years and Above (includes corresponding Graph/Chart)
    • Table 22: Prevalence of High Blood Pressure in US Adult Population by Gender and Age (2009-2012): Prevalence Percentage of CVDs for Males and Females of Age Groups - 20-34 Years, 35-44 Years, 45-54 Years, 65-74 Years, and 75 Years & Above (includes corresponding Graph/Chart)
    • Table 23: Prevalence of Diabetes and Obesity in US Adult Population by Gender (2009-2012): Prevalence Percentage of Physician Diagnosed Diabetes, Undiagnosed Diabetes, and Obesity for Males and Females of Age 20 Years & Above (includes corresponding Graph/Chart)
    • Table 24: US Total Annual Average Expenditure for Cardiovascular Diseases by Type of CVD (2015): Percentage Breakdown of Expenditure for Heart Disease, Hypertension, Stroke and Other CVDs (includes corresponding Graph/Chart)
    • Product Introductions & Approvals
    • Strategic Corporate Developments
    • Select Key Players
  • B. Market Analytics
    • Cardiac Biomarkers Testing By Location of Testing
    • Table 25: The US Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 26: The US Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 27: The US 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
    • Cardiac Biomarkers Market by Assay Test Type
    • Table 28: The US Recent Past, Current and Future Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 29: The US Historic Review Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 30: The US 14-Year Perspective for Cardiac Biomarkers by Test Type - Percentage Breakdown of Dollar Revenues for Cardiac Troponin, BNP & NT-proBNP, and Others Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Current and Future Analysis
    • Strategic Corporate Development
    • Select Key Player
  • B. Market Analytics
    • Table 31: Canadian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 32: Canadian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 33: Canadian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Current and Future Analysis
    • LSI Medience Corporation - A Key Japanese Player
  • B. Market Analytics
    • Table 34: Japanese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 35: Japanese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 36: Japanese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Growing Prevalence of Cardiovascular Disease Propels Growth of European Cardiac Biomarkers Market
    • Cardiac Markers in Primary Care Sector
  • B. Market Analytics
    • Table 37: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 38: European Historic Review Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 39: European 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
    • Cardiac Biomarkers Testing By Location of Testing
    • Table 40: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 41: European Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 42: European 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
    • Cardiac Biomarkers Market by Assay Test Type
    • Table 43: European Recent Past, Current and Future Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 44: European Historic Review Analysis for Cardiac Biomarkers by Test Type - Cardiac Troponin, BNP & NT-proBNP, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 45: European 14-Year Perspective for Cardiac Biomarkers by Test Type - Percentage Breakdown of Dollar Revenues for Cardiac Troponin, BNP & NT-proBNP, and Others Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current and Future Analysis
    • Select Key Player
  • B. Market Analytics
    • Table 46: French Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 47: French Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 48: French 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4b. GERMANY

  • Market Analysis
    • Table 49: German Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 50: German Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 51: German 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 52: Italian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 53: Italian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 54: Italian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current and Future Analysis
    • Randox Laboratories Ltd. - A Key Player
  • B. Market Analytics
    • Table 55: The UK Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 56: The UK Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 57: The UK 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 58: Spanish Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 59: Spanish Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 60: Spanish 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 61: Russian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 62: Russian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 63: Russian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Current and Future Analysis
    • Product Introductions & Approvals
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 64: Rest of Europe Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 65: Rest of Europe Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 66: Rest of Europe 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • Market Analysis
    • Table 67: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 68: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 69: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
    • Cardiac Biomarkers Testing By Location of Testing
    • Table 70: Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 71: Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 72: Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Current and Future Analysis
    • Product Introductions & Approval
  • B. Market Analytics
    • Table 73: Chinese Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 74: Chinese Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 75: Chinese 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

5b. INDIA

  • Market Analysis
    • Table 76: Indian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 77: Indian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 78: Indian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Boditech Med Inc. (South Korea) - A Key Player
  • B. Market Analytics
    • Table 79: Rest of Asia-Pacific Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 80: Rest of Asia-Pacific Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 81: Rest of Asia-Pacific 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 82: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 83: Latin American Historic Review Analysis for Cardiac Biomarkers by Geographic Region - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 84: Latin American 14-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Dollar Revenues for Brazil, and Rest of Latin America Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)
    • Cardiac Biomarkers Testing By Location of Testing
    • Table 85: Latin American Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 86: Latin American Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 87: Latin American 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

6a. BRAZIL

  • Market Analysis
    • Table 88: Brazilian Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 89: Brazilian Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 90: Brazilian 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

6b. REST OF LATIN-AMERICA

  • Market Analysis
    • Table 91: Rest of Latin-America Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 92: Rest of Latin-America Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 93: Rest of Latin-America 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • Market Analysis
    • Table 94: Rest of World Recent Past, Current and Future Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)
    • Table 95: Rest of World Historic Review Analysis for Cardiac Biomarkers by Location of Testing - Laboratory Testing & Point-of-Care Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart)
    • Table 96: Rest of World 14-Year Perspective for Cardiac Biomarkers by Location of Testing - Percentage Breakdown of Dollar Revenues for Laboratory Testing & Point-of-Care Testing Markets for Years 2009, 2016, and 2022 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top